274 related articles for article (PubMed ID: 29381228)
1. Implications of intercorrelation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide.
Doki K; Darwich AS; Achour B; Tornio A; Backman JT; Rostami-Hodjegan A
Br J Clin Pharmacol; 2018 May; 84(5):972-986. PubMed ID: 29381228
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes.
Kudo T; Hisaka A; Sugiyama Y; Ito K
Drug Metab Dispos; 2013 Feb; 41(2):362-71. PubMed ID: 23139378
[TBL] [Abstract][Full Text] [Related]
3. Quantitative Analysis of Complex Drug-Drug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data.
Kim SJ; Toshimoto K; Yao Y; Yoshikado T; Sugiyama Y
J Pharm Sci; 2017 Sep; 106(9):2715-2726. PubMed ID: 28479356
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide.
Varma MV; Lai Y; Kimoto E; Goosen TC; El-Kattan AF; Kumar V
Pharm Res; 2013 Apr; 30(4):1188-99. PubMed ID: 23307347
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2005 Oct; 97(4):249-56. PubMed ID: 16176562
[TBL] [Abstract][Full Text] [Related]
6. Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole.
Türk D; Hanke N; Wolf S; Frechen S; Eissing T; Wendl T; Schwab M; Lehr T
Clin Pharmacokinet; 2019 Dec; 58(12):1595-1607. PubMed ID: 31129789
[TBL] [Abstract][Full Text] [Related]
7. Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.
Marzolini C; Rajoli R; Battegay M; Elzi L; Back D; Siccardi M
Clin Pharmacokinet; 2017 Apr; 56(4):409-420. PubMed ID: 27599706
[TBL] [Abstract][Full Text] [Related]
8. Estimation of the Contribution of CYP2C8 and CYP3A4 in Repaglinide Metabolism by Human Liver Microsomes Under Various Buffer Conditions.
Kudo T; Goda H; Yokosuka Y; Tanaka R; Komatsu S; Ito K
J Pharm Sci; 2017 Sep; 106(9):2847-2852. PubMed ID: 28238899
[TBL] [Abstract][Full Text] [Related]
9. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.
Bidstrup TB; Bjørnsdottir I; Sidelmann UG; Thomsen MS; Hansen KT
Br J Clin Pharmacol; 2003 Sep; 56(3):305-14. PubMed ID: 12919179
[TBL] [Abstract][Full Text] [Related]
10. Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk.
Gertz M; Tsamandouras N; Säll C; Houston JB; Galetin A
Pharm Res; 2014 Sep; 31(9):2367-82. PubMed ID: 24623479
[TBL] [Abstract][Full Text] [Related]
11. CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.
Backman JT; Honkalammi J; Neuvonen M; Kurkinen KJ; Tornio A; Niemi M; Neuvonen PJ
Drug Metab Dispos; 2009 Dec; 37(12):2359-66. PubMed ID: 19773535
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance.
Säll C; Houston JB; Galetin A
Drug Metab Dispos; 2012 Jul; 40(7):1279-89. PubMed ID: 22451699
[TBL] [Abstract][Full Text] [Related]
13. Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats.
Giri P; Delvadia P; Ladani MK; Prajapati N; Gupta L; Patel N; Joshi V; Giri S; Jain MR; Srinivas NR; Patel PR
Eur J Pharm Sci; 2019 Mar; 130():107-113. PubMed ID: 30633968
[TBL] [Abstract][Full Text] [Related]
14. Creation of Novel Sensitive Probe Substrate and Moderate Inhibitor Models for a Comprehensive Prediction of CYP2C8 Interactions for Tucatinib.
Templeton IE; Rowland-Yeo K; Jones HM; Endres CJ; Topletz-Erickson AR; Sun H; Lee AJ
Clin Pharmacol Ther; 2024 Feb; 115(2):299-308. PubMed ID: 37971208
[TBL] [Abstract][Full Text] [Related]
15. Accounting for inter-correlation between enzyme abundance: a simulation study to assess implications on global sensitivity analysis within physiologically-based pharmacokinetics.
Melillo N; Darwich AS; Magni P; Rostami-Hodjegan A
J Pharmacokinet Pharmacodyn; 2019 Apr; 46(2):137-154. PubMed ID: 30905037
[TBL] [Abstract][Full Text] [Related]
16. Interplay of UDP-Glucuronosyltransferase and CYP2C8 for CYP2C8 Mediated Drug Oxidation and Its Impact on Drug-Drug Interaction Produced by Standardized CYP2C8 Inhibitors, Clopidogrel and Gemfibrozil.
Iga K; Kiriyama A
Clin Pharmacokinet; 2024 Jan; 63(1):43-56. PubMed ID: 37921907
[TBL] [Abstract][Full Text] [Related]
17. Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development.
Cleary Y; Gertz M; Morcos PN; Yu L; Youdim K; Phipps A; Fowler S; Parrott N
Clin Pharmacol Ther; 2018 Sep; 104(3):505-514. PubMed ID: 29226313
[TBL] [Abstract][Full Text] [Related]
18. Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.
Wu F; Krishna G; Surapaneni S
Cancer Chemother Pharmacol; 2020 Oct; 86(4):461-473. PubMed ID: 32886148
[TBL] [Abstract][Full Text] [Related]
19. Physiologically based pharmacokinetics model predicts the lack of inhibition by repaglinide on the metabolism of pioglitazone.
Xiao Q; Tang L; Xu R; Qian W; Yang J
Biopharm Drug Dispos; 2015 Dec; 36(9):603-12. PubMed ID: 26296069
[TBL] [Abstract][Full Text] [Related]
20. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide.
Kajosaari LI; Niemi M; Backman JT; Neuvonen PJ
Clin Pharmacol Ther; 2006 Mar; 79(3):231-42. PubMed ID: 16513447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
